Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Oral Health · All outcomes

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 5 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Presence/absence of HSV oral lesions · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

Prophylactic valaciclovir (lower dose) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (higher dose); GRADE not reported.

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
RR 0.23 [0.05, 1.03]
2 studies · 181 participants
GRADE not reported

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Viral isolates · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
Orlowski 2004: 182 throat swabs performed for patients receiving 500 mg of valaciclovir (n = 40) and 198 swabs for those receiving 1000 mg (n = 41); all of the cultures proved negative (1 trial, 81; not estimable).
1 study · 81 participants
GRADE not reported

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Adverse effects · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
One study reported adverse effects (Warkentin 2002). Twenty patients allocated to receive high dose valaciclovir reported adverse effects (42%); for the low dose group this number was 27 (52%). Adverse effects were…
1 study · 100 participants
GRADE not reported

Prophylactic aciclovir (oral or intravenous) vs Prophylactic valaciclovir (oral)

Presence/absence of HSV oral lesions · Patients being treated for cancer (predominantly haematological malignancies)

Prophylactic aciclovir (oral or intravenous) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (oral); GRADE not reported.

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
RR 0.78 [0.26, 2.38]
2 studies · 181 participants
GRADE not reported

Prophylactic aciclovir (oral or intravenous) vs Prophylactic valaciclovir (oral)

Cost of oral care · Patients being treated for cancer (predominantly haematological malignancies)

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
Only one trial reported on the cost of prophylaxis for HSV (Liesveld 2002). The reported mean pharmacy costs for those randomised to receive aciclovir were $1080 compared to $320 for those initially randomised to…
1 study · 30 participants
GRADE not reported